Glufosfamide: Can we improve the process of anticancer agent development?

Expert Opinion on Investigational Drugs

Volumn 21, Issue 5, 2012, Pages 749-754

  Lacombe, Denis ^a  

^a EORTC DATA CENTER   (Belgium)

Author keywords

Anticancer agent; Clinical trials; Drug development; Glufosfamide

Indexed keywords

ACROLEIN; BEVACIZUMAB; CREATININE; DRUG METABOLITE; GEMCITABINE; GLUCOSE; GLUFOSFAMIDE; MEMBRANE RECEPTOR;

ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER PATIENT; CELL PROLIFERATION; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIARRHEA; DRUG DOSE INCREASE; DRUG MECHANISM; DRUG SAFETY; DRUG UPTAKE; FATIGUE; GLIOMA; HUMAN; HYPOKALEMIA; HYPOPHOSPHATEMIA; INFECTION; KIDNEY TUBULE ACIDOSIS; LUNG NON SMALL CELL CANCER; METABOLIC ACTIVATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; RECOMMENDED DRUG DOSE; SIDE EFFECT; THROMBOCYTOPENIA; TUMOR CELL; VOMITING;

ALKYLATING AGENTS; ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DISCOVERY; GLUCOSE; HUMANS; IFOSFAMIDE; NEOPLASMS;

EID: 84859728193     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2012.670218     Document Type: Article

References (16)

1. Mazur L, Opydo-Chanek M, Stojak M. Glufosfamide as a new oxazaphosphorine anticancer agent. Anticancer Drugs 2011;6:488-93
2. Asta Medica Glufosfamide investigator's brochure
3. Briasoulis E, Judson I, Pavlidis N, et al. Phase I trial of 6-hour infusion of glufosfamide, a new alkylating agent with potentially enhanced selectivity for tumors that overexpress transmembrane glucose transporters: a study of the EORTC Early Clinical Studies Group. J Clin Oncol 2000;18(20):3535-44
4. Shimizu T, Okamoto I, Tamura K, et al. Phase I clinical and pharmacokinetic study of the glucose-conjugated cytotoxic agent D-19575 (glufosfamide) in patients with solid tumors. Cancer Chemother Pharmacol 2010;65(2):243-50
5. Giaccone G, Smit EF, de Jonge M, et al. Glufosfamide administered by 1-hour infusion as second line treatment for advanced non cell lung cancer; a phase II trial of the EORTC New Drug Development Group. Eur J Cancer 2004;40(5):667-72 (Pubitemid 38326615)
6. Briasoulis E, Pavlidis N, Terret C, et al. Glufosfamide administered using a 1-hour infusion given as first line treatment for advanced pancreatic cancer. A phase II trial of the EORTC New Drug Development Group. Eur J Cancer 2003;39(16):2334-40 (Pubitemid 37214857)
7. Van den Bent MJ, Grisold W, Frappaz D, et al. European Organization for Research and Treatment of Cancer (EORTC) open label phase II study on glufosfamide administered as a 60-minute infusion every 3 weeks in recurrent glioblastoma multiforme. Ann Oncol 2003;14(12):1732-4 (Pubitemid 38029044)
8. Therasse P, Arbuck SG, Eisenhauer EA, et al. New Guidelines to evaluate the response to treatment in solid tumors. JNCI 2000;92(3):205-16 (Pubitemid 30099779)
9. Macdonald DR, Cascino TL, Schold SC, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990;8:1277-80 (Pubitemid 20195640)
10. Chiorean EG, Dragovich T, Hamm J, et al. A phase I dose escalation study of glufosfamide in combination with gemcitabine in solid tumors including pancreatic adenocarcinoma. Cancer Chemother Pharamcol 2008;61(6):1019-26 (Pubitemid 351423130)
11. Chiorean EG, Dragovitch T, Hamm J, et al. A phase II trial of glufosfamide in combination with gemcitabine in chemotherapy naive pancreatic adenocarcinoma. Am J Clin Oncol 2010;33(2):111-16
12. Ciuleanu TE, Pavlovsky AV, Bodoky G, et al. A randomized phase III trial of glufosfamide compared with best supportive care in metastatic pancreatic adenocarcinoma previously treated with gemcitabine. Eur J Cancer 2009;45(9):1589-96
13. Ratain MJ, Sargent DJ. Optimising the design of phase II oncology trials: the importance of randomisation. Eur J Cancer 2009;45(2):275-80
14. Kindler HL, Niedzwiecki D, Hollis D, et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol 2010;28(22):3617-22
15. Kindler HL, Friberg G, Singh DA, et al. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 2005;23(31):8033-40 (Pubitemid 46657405)
16. Van den Bent MJ, Brandes AA, Rampling R, et al. Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. J Clin Oncol 2009;27(8):1268-74